NEW YORK (GenomeWeb News) – For the second quarter ended June 30, Genomic Health reported revenues of $63.7 million, compared to $57.6 million during the same period last year, marking an 11 percent increase.

However, the firm fell short of Wall Street's estimates for the top and bottom line.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.